Alexandru Stieber/LinkedIn
Dec 18, 2025, 13:34
Alexandru Stieber Explores VEXAS Syndrome
Alexandru Stieber, Internal Medicine Resident at SUUMC Bucharest, shared on LinkedIn:
”Second set of scientific updates from the SNFMI Congress that took place last week in Tours, France.
The theme of today’s post revolves around VEXAS syndrome, new implications for patients with a VEXAS-like phenotype and the evolving concept of “clonal hematopoiesis of immunological significance” (CHIS).
- proven efficacy of azacitidine treatment in VEXAS patients, even in the absence of myelodysplastic syndrome
- proven pathophysiology of UBA1 mutated myeloid cells that drive an inflammatory millieu which alters normal hematopoiesis
- new links found between clonalhematopoiesis with IDH mutations and inflammatory manifestations (polymyalgia rheumatica and large-vessel vasculitis), with resolution under targeted inhibitors”
Stay updated with Hemostasis Today.
-
May 25, 2026, 11:20Abdul Mannan: Why Thalassaemia Is More Than Low Haemoglobin
-
May 25, 2026, 11:06Roberta Gualtierotti: Iron Is More Than a Hematologic Parameter
-
May 25, 2026, 11:03Divyaswathi Citla Sridhar: How Bone Health Is Impacted in Bleeding Disorders
-
May 25, 2026, 10:48Ama Ameyaw: Beginning My Research Journey in HIT and Platelet Immunology at the Wen Lab
-
May 25, 2026, 10:46Fredrick Chalinga: Negative DAT Does Not Mean No Hemolysis
-
May 25, 2026, 10:41Mukaram Rana: Anticoagulation-Free VV-ECMO for Trauma-Induced Pulmonary Haemorrhage in Fontan Physiology
-
May 25, 2026, 10:30Rob Mac Sweeney: Prevention and Treatment of Thrombosis in Patients With Decompensated Cirrhosis
-
May 25, 2026, 07:34Wolfgang Miesbach: The Maastricht Bleeding Cohort and The High Prevalence of BDUC in Women
-
May 25, 2026, 07:31Maya Brown-Zimmerman: Bridging Patient Experience and Genetic Counseling in Marfan Syndrome